Projects funded by the NCN

Information on the principal investigator and host institution

Information of the project and the call

Keywords

Equipment

Delete all

Search results

127 projects found matching your search criteria :

  1. TP53 mutations drive alternative FGFR1 splicing - the study of consequences for cancer progression and therapeutic oppor...

    Call: PRELUDIUM 24 , Panel: NZ4

    Principal investigator: Weronika Wojtyś

    Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN

  2. Development of Red-Emitting Chiral Carbon Dots for Advanced Photodynamic Therapy (PDT)

    Call: PRELUDIUM 24 , Panel: ST8

    Principal investigator: Patryk Szymaszek

    Politechnika Krakowska im. Tadeusza Kościuszki

  3. Development of novel 1,3-selenazol-2-one derivatives incorporated into self-emulsifying drug delivery systems as a strat...

    Call: OPUS 29 , Panel: NZ7

    Principal investigator: dr hab. Robert Czarnomysy

    Uniwersytet Medyczny w Białymstoku

  4. New violacein derivatives as candidates for sonodynamic therapy against skin cancer

    Call: SONATINA 9 , Panel: NZ7

    Principal investigator: dr Daniel Ryszard Ziental

    Uniwersytet Przyrodniczy w Poznaniu

  5. Next-Generation Exosome Therapy: Engineering NK Cell-Derived Vesicles for Targeted Cancer Treatment

    Call: SONATINA 9 , Panel: NZ6

    Principal investigator: dr Daria Nawrocka

    Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda Polskiej Akademii Nauk

  6. Mind the gap! Plasmonic nanocavity for spectroscopic trapping of local molecularrearrangements in DNA upon epigenetic mo...

    Call: OPUS 28 , Panel: ST4

    Principal investigator: prof. Ewelina Wioletta Lipiec

    Uniwersytet Jagielloński

  7. Janus nanoparticles - research on the effect of the duality of carriers of the activesubstance in targeted therapy of sk...

    Call: OPUS 28 , Panel: ST8

    Principal investigator: dr hab. Bożena Anna Tyliszczak

    Politechnika Krakowska im. Tadeusza Kościuszki

  8. Investigation of the mechanism of enhanced liposome delivery to tumors and its application for dual target immunotherapy

    Call: OPUS 28 , Panel: NZ7

    Principal investigator: dr hab. Tomasz Piotr Rygiel

    Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN

  9. Environmental modulation of CDK4/6 inhibitor efficacy: Impact of mycotoxin alternariol exposure on anti-cancer therapies

    Call: SONATA 20 , Panel: NZ5

    Principal investigator: dr Anna Dominika Walczak-Szeffer

    Uniwersytet Medyczny w Łodzi

  10. Neutrophil Dynamics: Unveiling Anti-Tumor and Therapy Efficacy with the TUmor Neutrophil Immunotherapy on Chip (TUNIC) m...

    Call: SONATA 20 , Panel: NZ6

    Principal investigator: dr Martin Nurmik

    Międzynarodowy Instytut Mechanizmów i Maszyn Molekularnych Polskiej Akademii Nauk

  11. Quad-TNT: Quadruplex-Targeted Photo-Therapy for Triple-Negative Tumors

    Call: SONATA BIS 14 , Panel: NZ5

    Principal investigator: dr Marco Deiana

    Politechnika Wrocławska

  12. Synthesis of novel hybrid nanomaterials based on fullerene scaffold for photodynamic therapy of cancer

    Call: PRELUDIUM 23 , Panel: NZ7

    Principal investigator: Dominik Jakub Dreszer

    UNIWERSYTET ŚLĄSKI

  13. Extensive analysis of the immunological profile of pediatric patients with acute lymphoblastic leukemia in order to iden...

    Call: PRELUDIUM 22 , Panel: NZ5

    Principal investigator: Anna Krętowska-Grunwald

    Uniwersytet Medyczny w Białymstoku

  14. Development of dual immuno-oligo- biosensors for monitoring and controlling of the metastatic colorectal cancer and inve...

    Call: OPUS 25 , Panel: ST4

    Principal investigator: dr hab. Magdalena Stobiecka

    Szkoła Główna Gospodarstwa Wiejskiego w Warszawie, Instytut Biologii

  15. Anticancer potential of TMPyP4 porphyrin in breast cancer photodynamic therapy and evaluation of the treatment safety

    Call: OPUS 25 , Panel: NZ7

    Principal investigator: prof. Błażej Rubiś

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  16. Targeting Energy Metabolism for Precision Cancer Therapy: Novel Inhibitors of LDH-A and PDK1 as Potential Strategies to ...

    Call: PRELUDIUM 22 , Panel: NZ7

    Principal investigator: Marika Anna Frańczak

    Gdański Uniwersytet Medyczny, Wydział Lekarski

  17. Investigating the anti-cancerous effect of antioxidant extract from spent coffee grounds on the functioning of normal an...

    Call: PRELUDIUM 22 , Panel: NZ5

    Principal investigator: Adrianna Maria Piasek

    Politechnika Warszawska, Wydział Chemiczny

  18. Targeted poloxamer micelles with selected drugs as a strategy for overcoming the mechanisms of multidrug resistance in p...

    Call: PRELUDIUM BIS 4 , Panel: NZ7

    Principal investigator: prof. Tomasz Adam Gośliński

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  19. Research on the preparation of new, hydrogel nanosystems for targeted therapy of colorectal cancer

    Call: SONATA 18 , Panel: NZ7

    Principal investigator: dr Urszula Helena Piotrowska

    Warszawski Uniwersytet Medyczny

  20. Molecular insights into hypoxic tumors – for development of targeted cancer therapeutics

    Call: POLONEZ BIS 3 , Panel: NZ5

    Principal investigator: dr Marco Deiana

    Politechnika Wrocławska

  21. Oncogene competition - a new interplay mechanism of mutant p53 with CMYC and mutant KRAS in human cancers.

    Call: OPUS 23 , Panel: NZ5

    Principal investigator: dr hab. Dawid Włodzimierz Walerych

    Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN

  22. Bisphosphonate complexes based on103Pd/103mRh in vivo generator for Auger electron therapy of bone cancer metastases

    Call: OPUS 23 , Panel: ST4

    Principal investigator: prof. Aleksander Józef Bilewicz

    Instytut Chemii i Techniki Jądrowej

  23. Pancreatic cancer oxygenation as a prognostic marker during anticancer therapy

    Call: OPUS 23 , Panel: NZ5

    Principal investigator: dr Martyna Krzykawska-Serda

    Uniwersytet Jagielloński, Wydział Biochemii, Biofizyki i Biotechnologii

  24. Structure-guided design of histone demethylase inhibitors for cancer therapy.

    Call: SONATA 17 , Panel: NZ7

    Principal investigator: dr Piotr Henryk Małecki

    Instytut Chemii Bioorganicznej PAN

  25. Light-producing, oxygen-delivering, cancer cell-targeted carriers for photosensitisers dedicated for photodynamic therap...

    Call: OPUS 22 , Panel: NZ7

    Principal investigator: prof. Marek Arkadiusz Murias

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  26. The interplay of neurochemistry and cancer biology: in the search for novel glioblastoma multiforme therapy among dopami...

    Call: SONATA 17 , Panel: NZ7

    Principal investigator: dr Katarzyna Maria Kucwaj-Brysz

    Uniwersytet Jagielloński, Collegium Medicum

  27. FGFR2-->JunB axis in progression of ER+ breast cancer - molecular analyses and prognostication

    Call: PRELUDIUM BIS 3 , Panel: NZ3

    Principal investigator: dr hab. Rafał Sebastian Sądej

    Gdański Uniwersytet Medyczny, Międzyuczelniany Wydział Biotechnologii Uniwersytetu Gdańskiego i Gdańskiego Uniwersytetu Medycznego

  28. RE-SENSE: Dual-loaded lipid nanoparticles to overcome the resistance of non-small cell lung cancer cells to personalized...

    Call: PRELUDIUM 20 , Panel: NZ7

    Principal investigator: Mikołaj Czajkowski

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  29. Breast cancer metastasis-induced endothelial-mesenchymal transition alongside ageing; implications for therapy

    Call: OPUS 21 , Panel: NZ5

    Principal investigator: dr hab. Marta Maria Smęda

    Uniwersytet Jagielloński, Jagiellońskie Centrum Rozwoju Leków (JCET)

  30. Synthetic epidermal growth factor receptor inhibitor conjugated with nobel metal nanoparticles as a potential drug for t...

    Call: PRELUDIUM 20 , Panel: NZ7

    Principal investigator: Shaoshan Mai

    Gdański Uniwersytet Medyczny, Wydział Farmaceutyczny

  31. MLK4 signaling in DNA damage response and cancer therapy

    Call: PRELUDIUM 20 , Panel: NZ3

    Principal investigator: Dawid Grzegorz Mehlich

    Międzynarodowy Instytut Mechanizmów i Maszyn Molekularnych Polskiej Akademii Nauk

  32. In search for molecular targets to overcome doxorubicin resistance in triple-negative breast cancer with the use of inno...

    Call: PRELUDIUM 20 , Panel: NZ7

    Principal investigator: Anna Karolina Pogorzelska

    Narodowy Instytut Leków

  33. Molecular and cellular landscape of pulmonary and hepatic metastases of colorectal cancer with potential clinical implic...

    Call: PRELUDIUM 20 , Panel: NZ4

    Principal investigator: dr Marta Aleksandra Popęda

    Gdański Uniwersytet Medyczny, Wydział Lekarski

  34. Reversible senescence as a new mechanism of cancer cell resistance for chemotherapy. Analysis of the mechanism of cancer...

    Call: SONATINA 5 , Panel: NZ3

    Principal investigator: dr Karolina Anna Staniak

    Politechnika Warszawska, Wydział Chemiczny

  35. On demand generation of singlet oxygen in organic solutions and water

    Call: OPUS 20 , Panel: ST4

    Principal investigator: dr Aleksander Gorski

    Instytut Chemii Fizycznej Polskiej Akademii Nauk

  36. Smart polymer delivery systems for photosensitizers to cancer cells

    Call: PRELUDIUM BIS 2 , Panel: NZ7

    Principal investigator: prof. Tomasz Adam Gośliński

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  37. FGF/FGFR-signalling in mediation of resistance to therapy in triple-positive breast cancer: clinical implications of PAM...

    Call: OPUS 20 , Panel: NZ4

    Principal investigator: dr hab. Hanna Maria Romańska-Knight

    Uniwersytet Medyczny w Łodzi, Wydział Lekarski

  38. Delivery of immuno-activators to phagocytic cells in order to obtain an anti-tumor response

    Call: OPUS 20 , Panel: NZ7

    Principal investigator: dr hab. Tomasz Piotr Rygiel

    Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN

  39. Drug repurposing to target p53 protein family for improved therapy in the relapsed TP53 and EGFR mutated lung cancer

    Call: OPUS 20 , Panel: NZ7

    Principal investigator: dr Joanna Elżbieta Zawacka-Pankau

    Warszawski Uniwersytet Medyczny

  40. Polymersomes specifically releasing cGAMP and doxorubicin in tumor hypoxic regions as a new anti-cancer therapeutic stra...

    Call: OPUS 20 , Panel: NZ5

    Principal investigator: dr hab. Ryszard Smolarczyk

    Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie, Oddział w Gliwicach

  41. The use of surface proteins to capture cancer cells with functionalized magnetic nanoparticles as an innovative theranos...

    Call: OPUS 20 , Panel: NZ5

    Principal investigator: dr hab. Joanna Danuta Dulińska-Litewka

    Uniwersytet Jagielloński, Collegium Medicum

  42. Identification of potential markers aiming early diagnostics of progression and tailoring metastasis-oriented therapies ...

    Call: OPUS 20 , Panel: NZ5

    Principal investigator: dr Natalia Bednarz-Knoll

    Gdański Uniwersytet Medyczny, Międzyuczelniany Wydział Biotechnologii Uniwersytetu Gdańskiego i Gdańskiego Uniwersytetu Medycznego

  43. Usefulness of liquid biopsy" in diagnostics, stratification, and monitoring of therapy in non-small cell lung cancer pat...

    Call: PRELUDIUM BIS 2 , Panel: NZ5

    Principal investigator: dr hab. Joanna Natalia Budna-Tukan

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Wydział Medyczny

  44. Increasing the precision of chimeric antigen receptor (CAR)-mediated anticancer immunotherapy by using the chemokine-ind...

    Call: OPUS 19 , Panel: NZ6

    Principal investigator: dr hab. Radosław Zagożdżon

    Warszawski Uniwersytet Medyczny

  45. Glucose and chitosan-modified PEG-ylated palladium nanoparticles with various size and shape as potential radiosensitize...

    Call: PRELUDIUM 19 , Panel: ST5

    Principal investigator: dr Bartosz Adrian Klębowski

    Instytut Fizyki Jądrowej im. Henryka Niewodniczańskiego PAN

  46. Photodynamic therapy combined with PD-1/PD-L1 blockade immunotherapy: new possibilities for the treatment of immunogenic...

    Call: OPUS 19 , Panel: NZ7

    Principal investigator: dr hab. Janusz Marcin Dąbrowski

    Uniwersytet Jagielloński, Wydział Chemii

  47. Exploring the mechanisms of therapy-facilitated metastasis and CAAX proteins-processing enzymes in liver cancer

    Call: OPUS 19 , Panel: NZ4

    Principal investigator: dr Jarosław Marek Cisowski

    Uniwersytet Jagielloński, Wydział Biochemii, Biofizyki i Biotechnologii

  48. Dual CBR1-AKR1C3 inhibitors as a new approach to improve effectiveness and safety of anthracycline therapy.

    Call: PRELUDIUM 19 , Panel: NZ7

    Principal investigator: Marek Andrzej Jamrozik

    Uniwersytet Jagielloński, Collegium Medicum

  49. Tyrosine-modified polyethylenimine polymers as a promising vectors for siRNA delivery in synergistic cancer immunotherap...

    Call: PRELUDIUM 19 , Panel: NZ5

    Principal investigator: Małgorzata Kubczak

    Uniwersytet Łódzki, Wydział Biologii i Ochrony Środowiska

  50. Application of small compounds in the epigenetic therapy of malignant brain gliomas

    Call: OPUS 19 , Panel: NZ5

    Principal investigator: prof. Mirosława Zofia Naskręt-Barciszewska

    Instytut Chemii Bioorganicznej PAN

O Narodowym Centrum Nauki

Finansowanie nauki

Współpraca zagraniczna

Centrum prasowe

Deklaracja dostępności
Przetwarzanie danych osobowych
Polityka cookies

Partnerzy